生命科学资讯

Lonza confirms outlook as it expects more contracts in coming months - Reuters

Lonza Receives Swissmedic Approval for Highly Potent Biologics Drug Product Filling Line in Stein (CH) - Technology Networks

CPHI 2025: Lonza Capsugel spotlights delivery tech and sustainability in nutraceuticals - nutritioninsight.com

GBCC and Lonza partner for apprenticeship program - NH Business Review

Lonza expands its GMP solutions for cell and gene therapy - SelectScience

Lonza Capsugel launches organic, vegan capsule line - SupplySide Supplement Journal

Lonza Receives Swissmedic Approval for Highly Potent Biologics Drug Product Filling Line in Stein (CH) - the-scientist.com

Is Now An Opportune Moment To Examine Lonza Group AG (VTX:LONN)? - Yahoo Finance

Lonza Group: Growth, Signs Of Overvaluation, And A New Management Cause Uncertainty - Seeking Alpha

Lonza Completes New Drug Product Filling Line in Stein, Switzerland - Contract Pharma

Biotechnology Market Therapeutic Innovations & Forecast Report 2025-2033 Featuring Lonza, Amgen, Syngenta, Biocon, Biogen, F. Hoffmann-La Roche, Novartis, Novo Nordisk A/S, Pfizer, and Seagen - ResearchAndMarkets.com - Business Wire

Lonza Expands TheraPEAK® Portfolio to Strengthen Support for Gene and Cell Therapy Development - Lab Manager

Lonza Expands Cell and Gene Therapy Portfolio - Contract Pharma

Lonza Announces Innovation Day at SupplySide Global - WholeFoods Magazine

Lonza announces new board nominee - The Vacaville Reporter

Lonza’s Synaffix Collaborates with Qurient Therapeutics on Dual-Payload ADC Development - GEN - Genetic Engineering and Biotechnology News

Lonza’s Synaffix and Qurient team up on dual-payload ADC - The Pharma Letter

RION engages Lonza to scale manufacturing exosome based therapeutics - News-Medical

Lonza's Synaffix Collaborates with Qurient Therapeutics to Enable Development of Dual-Payload ADC - Yahoo Finance

RION Engages Lonza to Scale Manufacturing Exosome Based Therapeutics - Business Wire